Kimia Tabib
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kimia Tabib has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Farzad Kobarfard
Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications - Ali Hossein Rezayan
Department of Nanobiotechnology and Biomimetics, School of Bioengineering, College of Interdisciplinary Science and Technology, University of Tehran, Tehran, Iran
1 shared publication - Davood Beiki
Research Center for Nuclear Medicine, Shariati Hospital
1 shared publication - Faramarz Mehrnejad
Department of Nanobiotechnology and Biomimetics, School of Life Sciences Engineering, College of Interdisciplinary Science and Technology, University of Tehran, Tehran 14395-1561, Iran
1 shared publication - Mitra Bayat
Phytochemistry Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication - Mohsen Amini
Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 24 June 2015
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 307 (2) , 1125-1134
HYNIC a bifunctional prosthetic group for the labelling of peptides with 99mTc and 18FDG
- 24 June 2015
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 307 (2) , 1125-1134
HYNIC a bifunctional prosthetic group for the labelling of peptides with 99mTc and 18FDG
- Open Access
- 11 December 2012
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 20 (1) , 90
Synthesis and biological evaluation of propargyl acetate derivatives as anti-mycobacterial agents
Background: The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has intensified efforts to discover novel drugs for tuberculosis (TB) treatment. Targeting the persistent state of Mtb, a condition in which Mtb is resistant to conventional drug therapies, is of particular interest. Methods: This study is focused on propargyl acetate derivatives. Eight molecules were designed based on propargyl alcohols and different acid anhydrides. Results: All the synthesized compounds and commercially available ones were evaluated for anti-tuberculosis activity. Conclusions: Inhibitors against Mtb have been identified and characterized for further development into potential novel anti-tubercular drugs.
- 11 December 2012
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 20 (1) , 90
Open AccessSynthesis and biological evaluation of propargyl acetate derivatives as anti-mycobacterial agents
Background: The emergence of multidrug-resistant strains of Mycobacterium tuberculosis (Mtb) has intensified efforts to discover novel drugs for tuberculosis (TB) treatment. Targeting the persistent state of Mtb, a condition in which Mtb is resistant to conventional drug therapies, is of particular interest. Methods: This study is focused on propargyl acetate derivatives. Eight molecules were designed based on propargyl alcohols and different acid anhydrides. Results: All the synthesized compounds and commercially available ones were evaluated for anti-tuberculosis activity. Conclusions: Inhibitors against Mtb have been identified and characterized for further development into potential novel anti-tubercular drugs.